Holen Sie sich die Stockscreener-App
1.82
2.25%
0.04
Handel nachbörslich:
1.80
-0.02
-1.10%
Tharimmune Inc Aktie (THAR) Neueste Nachrichten
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors - The Holland Sentinel
EON Resources Inc. Announcement - Worcester Telegram
AINOS (NASDAQ: AIMD) Signs Long-Form Interview and National TV Commercial Agreement with New to The Street - Lubbock Avalanche-Journal
Tharimmune announces key leadership changes to advance pipeline - Investing.com
Navy SEAL Commander Joins Biotech Developing Military Defense Against Weaponized Fentanyl - Stock Titan
Don Kim Resigns as CFO of Tharimmune effective immediatelySEC filing - MarketScreener
Interactive Strength Inc. (Nasdaq:TRNR) Closes Initial $55 Million Investment for Crypto Treasury Strategy and Begins Acquiring $FET - Lohud
Hawley Crescent Catering & Events Wins 2025 Consumer Choice Award for Catering Excellence in Durham Region - Cincinnati Enquirer
Tharimmune announces executive changes and new agreements - Investing.com Australia
Tharimmune announces executive changes and new agreements By Investing.com - Investing.com Nigeria
TharimmuneRandy Milby Resigns As CEO And Board Member - marketscreener.com
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar
Tharimmune Holds Annual Meeting, Elects Directors - TipRanks
Tharimmune (THAR) Appoints Strategic Advisor to Enhance TH104 De - GuruFocus
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - Jonesboro Sun
FDA Clears Path for Tharimmune's Military Fentanyl Defense Drug as Navy SEAL Commander Joins Advisory Team - Stock Titan
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Tharimmune, Inc. SEC 10-Q Report - TradingView
Tharimmune appoints new executive chairman By Investing.com - Investing.com India
Tharimmune appoints new executive chairman - Investing.com Australia
Tharimmune IncAppoints Vincent Lopriore As Executive ChairmanSEC Filing - marketscreener.com
Tharimmune (THAR) Reports Promising Phase 1 Results for TH104 Bu - GuruFocus
Tharimmune (THAR) Advances TH104 as Key Medical Countermeasure | - GuruFocus
Tharimmune advances opioid prophylaxis drug TH104 - Investing.com
Tharimmune advances opioid prophylaxis drug TH104 By Investing.com - Investing.com South Africa
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Weatherford Democrat
Tharimmune's New Drug Breakthrough: FDA Fast-Tracks Military Protection Against Weaponized Fentanyl - Stock Titan
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Chronicle-Tribune
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Bluefield Daily Telegraph
Stocks of Tharimmune Inc (THAR) are poised to climb above their peers - Sete News
Breakthrough Drug TH104 Clinical Data Selected for Two Premier Medical Conferences DDW and EASL - Stock Titan
Tharimmune Appoints Clay Kahler And Gary Stetz To Board - citybiz
Tharimmune (THAR) Expands Board with New Appointments | THAR Sto - GuruFocus
Tharimmune expands board with two new directors By Investing.com - Investing.com India
Tharimmune expands board with two new directors - Investing.com
Tharimmune Adds $500M Success Story Entrepreneur and Financial Expert to Board Leadership - Stock Titan
Tharimmune Inc’s latest rating changes from various analysts - knoxdaily.com
Tharimmune Inc (THAR) Stock: Uncovering 52-Week Market Trends - investchronicle.com
These Numbers Show Just How Powerful Tharimmune Inc (NASDAQ: THAR) Stock Is - Stocksregister
Tharimmune expands board, appoints new directors By Investing.com - Investing.com Nigeria
Tharimmune expands board, appoints new directors - Investing.com
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats By Investing.com - Investing.com South Africa
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats - Investing.com Australia
Now Is The Time To Build A Position In Tharimmune Inc (NASDAQ:THAR) - Marketing Sentinel
Observations on the Tharimmune Inc (NASDAQ:THAR) Growth Curve - uspostnews.com
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug A - GuruFocus
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug Application | THAR Stock News - GuruFocus
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Joplin Globe
FDA Clears Path for Tharimmune's Military-Grade Fentanyl Defense Drug: No New Trials Needed - Stock Titan
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):